bioAffinity
  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Select Page

New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedure

by Maria Zannes | Mar 17, 2026 | Press Releases

CyPath® Lung improves diagnostic clarity in patients with multiple lung nodules In this case study, CyPath® Lung “Unlikely Malignancy” result supported physician’s decision to wait before ordering an invasive lung biopsy  In a clinical study, noninvasive CyPath® Lung...

bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung

by Maria Zannes | Mar 13, 2026 | Press Releases

Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company’s high-value CyPath® Lung test Number of CyPath® Lung tests performed in 2025 increased by 99% compared to 2024 Orders for CyPath® Lung by physicians and...

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

by Maria Zannes | Mar 10, 2026 | Press Releases

Study to evaluate clinical performance of CyPath® Lung for the early detection of lung cancer in high-risk patients  Murtha Cancer Center Research Program at Uniformed Services University of the Health Sciences provides support for longitudinal study  SAN ANTONIO, TX...

Sputum-Based Test May Identify Drug Targets in Asthma and COPD – Patient Care Online

by Maria Zannes | Mar 8, 2026 | Articles, News

By Christopher Gaida | Fact checked by Patrick Campbell https://www.patientcareonline.com/view/sputum-based-test-may-identify-drug-targets-in-asthma-copd Sputum flow cytometry identifies biologic targets (CD124/CD125) to personalize asthma and COPD treatment. New...

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

by Maria Zannes | Mar 3, 2026 | Press Releases

Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAI) Annual Meeting    Research demonstrates the technology’s ability to identify drug antibody receptors in sputum for two leading asthma...
« Older Entries

Categories

  • Articles (29)
  • Events (38)
  • News (54)
  • Press Releases (160)
  • Publications (19)

Recent Posts

  • New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedure March 17, 2026
  • bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung March 13, 2026
  • bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic March 10, 2026
  • Sputum-Based Test May Identify Drug Targets in Asthma and COPD – Patient Care Online March 8, 2026
  • bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients March 3, 2026
CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Copyright © 2023 bioAffinity Technologies, Inc.